application of real options valuation to r&d investments in ...

More documents

Recommendations

Info

12. Cox J.C. and R oss S .A . (1975), ―T he P ricing of O ptions for Jum p P rocess‖,Working Paper, Rodney L. White Centre for Financial Research, University ofPennsylvania13. CRM International/Scrip Reports (1999). The Pharmaceutical R&D Compendium:C M R International/Scrip’s Complete Guide to Trends in R&D, BS998. Richmond,UK: PJB Publications Ltd14. Dixit, A. K. and Pindyck, R. S. (1995), ―The Options Approach to CapitalInvestment‖, Harvard Business Review, May/Jun, Vol.73, Issue 3, pg.105-11515. Hayes, R. H. and Garvin, D. A. (1982), ―Managing as if Tomorrow Mattered‖,Harvard Business Review, May/June, pg.70-7916. Howell S. et al (2001), Real options : evaluating corporate investmentopportunities in a dynamic world, London : Financial Times Prentice Hall, 200117. Hodges, S. D. & Selby, M. J. P., (1987) "On the Evaluation of CompoundOptions" Management Science, 33 (3), 347-355.18. Howell, S., Stark, A., Newton, D., Paxson, D., Cavus, M., Pereira, J. and Patel, K.(2001), Real Options: Evaluating Corporate Investment Opportunities in ADynamic World, Financial Time/Prentice Hall: London, pg. 43-8919. Huchzermeier A. and Loch C.H (1998), ―E valuating R & D pro jects as R ealO ptions: w hy m ore variability is not alw ays better‖, W orking P aper, W H UKoblenz, INSEAD20. Hull, J. C. (2006), Options, Futures, and Other Derivatives, 6 th edition,Pearson/Prentice Hall:US21. Geske, R., (1977) "The Valuation of Corporate Liabilities as Compound Options‖Journal of Financial and Quantitative Analysis, Vol. 12, No. 4, UCLA, pp.541-552.22. Geske, R., (1979) "The Valuation of Compound Options", Journal of FinancialEconomics, 7, 63-8123. Jacob W and Hoon Kwak Y. (2003), In search of Innovative Techniques toEvaluate Pharmaceutical R&D, Technovation, Vol. 23 pp.291–296. Retrieved onPage | 72
31/08/2006, available at: http://home.gwu.edu/~kwak/PHARMA_R&D.pdf24. Lint O. and Pennings E. (1998), R&D as an option on market introduction, R&DManagement, Vol.28, Issue 4, p.279, October 1998, Retrieved on 31/08/2006,available at:http://www.blackwell-synergy.com/doi/abs/10.1111/1467-9310.0010425. Luehrman TA (1998a). Investment opportunities as real options: getting startedon the numbers. Harvard Business Review, 4, 51-6726. Luehrman TA (1998b). Strategy as a portfolio of real options. Harvard BusinessReview, 5, 89-9927. M erton R .C . (1976), ―O ption P ricing W hen U nderlying S tock R eturns arediscontinuous‖, Journal of Financial Economics, 3, 125-14428. Mun, J. (2002), Real Options Analysis: Tools and Techniques for ValuingStrategica) Investments and Decisions, John Wiley & Sons, Inc: New Jersey, pg.171-19329. Myers, S. C. (1987), ―Financial Theory and Financial Strategy‖, MidlandCorporate Finance Journal, 5, pg.6-1330. Mun, J. (2002), Real options analysis : tools and techniques for valuing strategicinvestments and decisions, New York: John Wiley & Sons31. Mun (2005), Real options analysis : tools and techniques for valuing strategicinvestments and decisions, New York: John Wiley & Sons32. N ew ton D , P axson D .A . and W iddick M (2004), ―R eal R & D O ptions‖,International Journal of Management Reviews, volume 5/6, issue 2 pp.113-130,retrieved on 31/08/2006, available at:http://www.blackwell-synergy.com/doi/full/10.1111/j.1460-8545.2004.00099.x33. Nichols NA (1994). Scientific management at Merck: an interview with CFOJudy Lewent. Harvard Business Review, 1, 88-9934. Oberholzer-G ee F. and N oorein Inam dar S . (2004), ―M erck‘s R ecall o f R ofecoxib:a S trategic P erspective‖, T he N ew E ngland Journal o f M edicine, V ol. 351 pp.2147-2149, Noverber 18, 2004, Number 21. Retrieved on 31/08/2006, availablePage | 73
Page 1 and 2:
APPLICATION OF REAL OPTIONS VALUATI
Page 3 and 4:
Table of ContentsAbstract .........
Page 5 and 6:
List of TablesTable 5.1: Value of O
Page 7 and 8:
Chapter One— IntroductionAs one o
Page 9 and 10:
Then, in Chapter 4, the case study
Page 11 and 12:
and we will have the right to take
Page 13 and 14:
project, to get its salvage value,
Page 15 and 16:
The option to switch:If assets have
Page 17 and 18:
2.2 Advantages of Real Option Valua
Page 19 and 20:
In the case of pharmaceutical R&D,
Page 21 and 22:
delayed in time. Undertaking one pr
Page 23 and 24:
Figure 2.2: Advantages and disadvan
Page 25 and 26:
smallest possible payoff of zero, w
Page 27 and 28: options applications is the binomia
Page 29 and 30: t: years to expirationr: annual ris
Page 31 and 32: Chapter Three— Apply Real options
Page 33 and 34: on Howell et al (2001).3.1.1 Precli
Page 35 and 36: approved.3.2 real options valuation
Page 37 and 38: Figure 3.3: Comparison of a call op
Page 39 and 40: applying the principals of activity
Page 41 and 42: that has occurred in the past. Depe
Page 43 and 44: Chapter Four— Case StudyFor this
Page 45 and 46: 4.3 DavanrikLAB Pharmaceuticals ori
Page 47 and 48: efficacious for depression only, a
Page 49 and 50: Chapter Five— Case Study Analysis
Page 51 and 52: figure below:Figure 5.3: NPV of Dav
Page 53 and 54: Merck & Co (10%), which gives $2338
Page 55 and 56: approval and other issues. Therefor
Page 57 and 58: of $345m at year 0 (which is $672.3
Page 59 and 60: project turns out to be unprofitabl
Page 61 and 62: these three options, the risk-free
Page 63 and 64: ewrite as, noting all the costs (in
Page 65 and 66: Figure 5.10: Valuation of Option A
Page 67 and 68: Figure 5.12: Valuation of Option A
Page 69 and 70: Figure 5.13 Valuation of Compound r
Page 71 and 72: $ in millionmillion to $113.97 mill
Page 73 and 74: Chapter Six— Limitations and conc
Page 75 and 76: discovery projects, arrives in a di
Page 77: References1. Amram M & Kulatilaka N
Page 81 and 82: 46. T rigeorgis L . (1995), ―M et
show all

application of real options valuation to r&d investments in ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?